<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMOXICILLIN AND CLAVULANATE POTASSIUM- amoxicillin and clavulanate potassiumÂ powder, for suspensionÂ </strong><br>Aidarex Pharmaceuticals LLC<br></p></div>
<h1>Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL<br>Powder for Oral Suspension</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_01c2a80b-1c61-4bec-8751-d2c0337598d8"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">1111<br>PRESCRIBING INFORMATION</span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the
                     effectiveness of Amoxicillin and Clavulanate Potassium 600 mg/42.9  mg per 5 mL and other
                     antibacterial drugs, Amoxicillin and Clavulanate Potassium 600 mg/42.9  mg per 5 mL should be used only to treat or prevent
                     <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by
                  bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_48f31c65-943a-4ba6-974b-99af52c4f7d3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Amoxicillin and Clavulanate Potassium 600 mg/42.9  mg per 5 mL is an oral antibacterial combination consisting of the
                     semisynthetic antibiotic amoxicillin and the Î²-lactamase inhibitor, clavulanate
                     potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of
                     ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic
                     acid. The amoxicillin molecular formula is
                        C<span class="Sub">16</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O<span class="Sub">5</span>Sâ€¢3H<span class="Sub">2</span>O, and
                     the molecular weight is 419.46. Chemically, amoxicillin is (2<span class="Italics">S</span>,5<span class="Italics">R</span>,6<span class="Italics">R</span>)-6-[(<span class="Italics">R</span>)-(-)-2-Amino-2-(<span class="Italics">p</span>-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic
                     acid trihydrate and may be represented structurally as:</p>
<div class="Figure"><img alt="Amoxicillin Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d13d3912-49e2-4a08-a62e-239730b15cd9&amp;name=amox-clav-pot-600-42-9-mg--5ml-sus-200ml-for-dr-re-1.jpg"></div>
<p>Clavulanic acid is produced by the fermentation of <span class="Italics">Streptomyces clavuligerus</span>. It is a Î²-lactam
                     structurally related to the penicillins and possesses the ability to inactivate
                     a wide variety of Î²-lactamases by blocking the active sites of these enzymes.
                     Clavulanic acid is particularly active against the clinically important
                     plasmid-mediated Î²-lactamases frequently responsible for transferred drug
                     resistance to penicillins and cephalosporins. The clavulanate potassium
                     molecular formula is C<span class="Sub">8</span>H<span class="Sub">8</span>KNO<span class="Sub">5</span>, and the
                     molecular weight is 237.25. Chemically, clavulanate potassium is potassium
                        (<span class="Italics">Z</span>)-(2<span class="Italics">R
                        </span>,5<span class="Italics">R</span>)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate
                     and may be represented structurally as:</p>
<div class="Figure"><img alt="Clavulanate Potassium Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d13d3912-49e2-4a08-a62e-239730b15cd9&amp;name=amox-clav-pot-600-42-9-mg--5ml-sus-200ml-for-dr-re-2.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a15a2a5a-029e-4082-82a1-5839c8f141e9"></a><a name="section-2.1"></a><p></p>
<h2>Inactive Ingredients:</h2>
<p class="First">Powder  for Oral  Suspension- Colloidal silicon dioxide, strawberry cream flavor, xanthan gum, aspartame<span class="Sup">a</span>, sodium carboxymethylcellulose, and silicon dioxide.</p>
<p><span class="Sup">a</span>Â Â See <a href="#LINK_989e6e1b-9690-41bc-b1a1-b41d2a0edbc8">PRECAUTIONS</a>â€”<a href="#LINK_c846fb32-1ae1-4dec-8b95-67f78f8890a5">Information for the Patient</a>/<a href="#LINK_9c2a3f3e-3a33-48c6-bb98-d1a599efabbe">Phenylketonurics</a>.<br><br></p>
<p>Each 5 mL of reconstituted 600 mg/42.9 mg per 5 mL oral suspension of Amoxicillin and Clavulanate Potassium contains 0.23 mEq potassium.
                        </p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_d0452769-1b11-4af0-b8c6-842d66d86f5d"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The pharmacokinetics of amoxicillin and clavulanate were determined in
                     a study of 19 pediatric patients, 8 months to 11 years, given Amoxicillin and
                     Clavulanate Potassium 600 mg/42.9 mg per 5 mL at an amoxicillin dose of 45
                     mg/kg q12h with a snack or meal. The mean plasma amoxicillin and
                     clavulanate pharmacokinetic parameter values are listed in the following table.
                  </p>
<table>
<caption><span>Table 1. Mean (Â±SD) Plasma Amoxicillin and Clavulanate Pharmacokinetic Parameter Values Following Administration of 45 mg/kg of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL Every 12 Hours to Pediatric Patients</span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<th class="Lrule Toprule" valign="top"> PARAMETER<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Lrule Toprule" valign="top"> AMOXICILLIN</th>
<th class="Lrule Rrule Toprule" valign="top"> CLAVULANATE</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Arithmetic mean Â± standard deviation, except T<span class="Sub">max</span> values which are medians (ranges).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" valign="top">Â C<span class="Sub">max</span> (mcg/mL)</td>
<td class="Lrule" valign="top">Â 15.7 Â± 7.7</td>
<td class="Lrule Rrule" valign="top">Â 1.7 Â± 0.9</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â T<span class="Sub">max</span> (hr)</td>
<td class="Lrule" valign="top">Â 2.0 (1.0 - 4.0)</td>
<td class="Lrule Rrule" valign="top">Â 1.1 (1.0 - 4.0)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â AUC<span class="Sub">0-t</span> (mcgâ‹…hr/mL)</td>
<td class="Lrule" valign="top">Â 59.8 Â± 20.0</td>
<td class="Lrule Rrule" valign="top">Â 4.0 Â± 1.9</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â T<span class="Sub">1/2</span> (hr)</td>
<td class="Lrule" valign="top">Â 1.4 Â± 0.3</td>
<td class="Lrule Rrule" valign="top">Â 1.1 Â± 0.3</td>
</tr>
<tr class="Last">
<td class="Lrule" valign="top">Â CL/F (L/hr/kg)</td>
<td class="Lrule" valign="top">Â 0.9 Â± 0.4</td>
<td class="Lrule Rrule" valign="top">Â 1.1 Â± 1.1</td>
</tr>
</tbody>
</table>
<p>The effect of food on the oral absorption of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL has not been studied.</p>
<p>Approximately 50% to 70% of the amoxicillin and approximately 25% to
                     40% of the clavulanic acid are excreted unchanged in urine during the first 6
                     hours after administration of 10 mL of 250 mg/5 mL suspension of amoxicillin
                     and clavulanate potassium.</p>
<p>Concurrent administration of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid.</p>
<p>Neither component in Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL is highly protein-bound; clavulanic acid has been found to be approximately 25% bound to human serum and amoxicillin approximately 18% bound.</p>
<p>Oral administration of a single dose of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL at 45 mg/kg (based on the amoxicillin component) to pediatric patients, 9 months to 8 years, yielded the following pharmacokinetic data for amoxicillin in plasma and middle ear fluid (MEF).</p>
<table>
<caption><span>Table 2. Amoxicillin Concentrations in Plasma and Middle Ear Fluid Following Administration of 45 mg/kg of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL to Pediatric Patients</span></caption>
<col width="20%">
<col width="20%">
<col width="30%">
<col width="30%">
<thead><tr class="First Last">
<th class="Lrule Toprule" align="center" colspan="2" valign="bottom"> Timepoint</th>
<th class="Lrule Toprule" align="center" valign="top"> Amoxicillin concentration in plasma (mcg/mL)</th>
<th class="Lrule Rrule Toprule" align="center" valign="top"> Amoxicillin concentration in MEF (mcg/mL)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="center" valign="top">Â 1 hour</td>
<td class="Lrule" align="center" valign="top">Â mean<br>median<br>range</td>
<td class="Lrule" align="center" valign="top">Â 7.7<br>9.3<br>1.5 - 14.0<br>(n = 5)</td>
<td class="Lrule Rrule" align="center" valign="top">Â 3.2<br>3.5<br>0.2 - 5.5<br>(n = 4)</td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">Â 2 hour</td>
<td class="Lrule" align="center" valign="top">Â mean<br>median<br>range</td>
<td class="Lrule" align="center" valign="top">Â 15.7<br>13.0<br>11.0 - 25.0<br>( n= 7)</td>
<td class="Lrule Rrule" align="center" valign="top">Â 3.3<br>2.4<br>1.9 - 6<br>(n = 5)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center" valign="top">Â 3 hour</td>
<td class="Lrule" align="center" valign="top">Â mean<br>median<br>range</td>
<td class="Lrule" align="center" valign="top">Â 13.0<br>12.0<br>5.5 - 21.0<br>(n = 5)</td>
<td class="Lrule Rrule" align="center" valign="top">Â 5.8<br>6.5<br>3.9 - 7.4<br>(n = 5)</td>
</tr>
</tbody>
</table>
<p>Dose administered immediately prior to eating.</p>
<br><p>Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid. The results of experiments involving the administration of clavulanic acid to animals suggest that this compound, like amoxicillin, is well distributed in body tissues.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1e6ccf23-de9f-4b45-bc21-de34225b5c2b"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology:</h2>
<p class="First">Amoxicillin is a semisynthetic antibiotic with a broad spectrum
                           of bactericidal activity against many gram-positive and gram-negative
                           microorganisms. Amoxicillin is, however, susceptible to degradation by
                           Î²-lactamases, and therefore, its spectrum of activity does not include
                           organisms which produce these enzymes. Clavulanic acid is a Î²-lactam,
                           structurally related to penicillin, which possesses the ability to
                           inactivate a wide range of Î²-lactamase enzymes commonly found in
                           microorganisms resistant to penicillins and cephalosporins. In
                           particular, it has good activity against the clinically important
                           plasmid-mediated Î²-lactamases frequently found responsible for transferred drug
                           resistance.</p>
<p>The clavulanic acid component of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL protects
                           amoxicillin from degradation by Î²-lactamase enzymes and effectively
                           extends the antibiotic spectrum of amoxicillin to include many bacteria
                           normally resistant to amoxicillin and other Î²-lactam antibiotics. Thus,
                           Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL possesses the distinctive properties of a broad-spectrum
                           antibiotic and a Î²-lactamase inhibitor.</p>
<p>Amoxicillin/clavulanic acid has been shown to be active against
                           most isolates of the following microorganisms, both in vitro and in
                           clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#LINK_baa2b5fc-4f3b-4d53-8b73-596109b9a059">INDICATIONS AND USAGE</a></span> section.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a98b88bb-5b25-4f2b-8edc-03ccea4e838f"></a><a name="section-3.1.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Aerobic Gram-Positive Microorganisms:</span></span></h3>
<p class="First"><span class="Italics">Streptococcus pneumoniae </span>
                                 (including isolates with penicillin MICs â‰¤ 2 mcg/mL)
                              </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c2e287f9-5f94-4f98-9140-676dc51df32c"></a><a name="section-3.1.2"></a><p></p>
<h3><span class="Italics"><span class="Bold">Aerobic Gram-Negative Microorganisms:</span></span></h3>
<p class="First"><span class="Italics">Haemophilus influenzae </span> (including Î²-lactamaseâ€“producing isolates)</p>
<p><span class="Italics">Moraxella catarrhalis </span>
                                 (including Î²-lactamaseâ€“producing isolates)</p>
<p>
                                 The following in vitro data are available, <span class="Bold">but their clinical significance is unknown.</span></p>
<p> At least 90% of the following microorganisms exhibit in
                                 vitro <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) less than or equal
                                 to the susceptible breakpoint for amoxicillin/clavulanic acid.
                                 However, the safety and efficacy of amoxicillin/clavulanic acid in
                                 treating <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been
                                 established in adequate and well-controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4d903329-d6f3-423b-a46c-bd342c7eeb9f"></a><a name="section-3.1.3"></a><p></p>
<h3><span class="Italics"><span class="Bold">Aerobic Gram-Positive Microorganisms:</span></span></h3>
<p class="First"><span class="Italics">Staphylococcus aureus </span>
                                 (including Î²-lactamaseâ€“producing isolates)
                              </p>
<p><span class="Bold"> NOTE: </span>
                                Staphylococci which are resistant to methicillin/oxacillin must be considered resistant to amoxicillin/clavulanic acid.</p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p><span class="Bold">NOTE: </span><span class="Italics">S. pyogenes</span> do not produce
                                 Î²-lactamase, and therefore, are susceptible to amoxicillin alone.
                                 Adequate and well-controlled clinical trials have established the
                                 effectiveness of amoxicillin alone in treating certain clinical
                                 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">S.
                                 pyogenes.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_29447493-0015-4044-b67a-27d8ede62ac2"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Test Methods:</h2>
<p class="First">When available, the clinical microbiology laboratory should
                           provide cumulative results of in vitro susceptibility test results for
                           antimicrobial drugs used in local hospitals and practice areas to the
                           physician as periodic reports that describe the susceptibility profile of
                           nosocomial and community-acquired pathogens. These reports should aid the
                           physician in selecting the most effective antimicrobial.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b5fa3671-a06e-4d1a-a967-4805548c58ee"></a><a name="section-3.2.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Dilution Technique:</span></span></h3>
<p class="First">Quantitative methods are used to determine antimicrobial
                                 <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of
                                 bacteria to antimicrobial compounds. The MICs should be determined
                                 using a standardized procedure.<span class="Sup">1,2</span> Standardized procedures are based
                                 on dilution methods (broth for <span class="Italics">S. pneumoniae </span>and <span class="Italics">H. influenzae</span>) or equivalent with
                                 standardized inoculum concentration and standardized
                                 concentrations of amoxicillin/clavulanate potassium powder. </p>
<p>The recommended dilution pattern utilizes a constant
                                 amoxicillin/clavulanate potassium ratio of 2 to 1 in all tubes with
                                 varying amounts of amoxicillin. MICs are expressed in terms of the
                                 amoxicillin concentration in the presence of clavulanic acid at a
                                 constant 2 parts amoxicillin to 1 part clavulanic acid. The MIC
                                 values should be interpreted according to criteria provided in
                                 Table 3.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_69b3c937-b74e-42ea-9f6d-a904bcd90523"></a><a name="section-3.2.2"></a><p></p>
<h3><span class="Italics"><span class="Bold">Diffusion Technique:</span></span></h3>
<p class="First">Quantitative methods that require measurement of zone
                                 diameters also provides reproducible estimates of the
                                 susceptibility of bacteria to antimicrobials. One such standardized
                                 technique requires the use of a standardized inoculum
                                 concentration.<span class="Sup">2,3</span> This procedure uses paper disks impregnated with
                                 30 mcg amoxicillin/clavulanate potassium (20 mcg amoxicillin plus
                                 10 mcg clavulanate potassium) to test susceptibility of
                                 microorganisms to amoxicillin/clavulanate potassium. Disk diffusion
                                 zone sizes should be interpreted according to criteria provided in
                                 Table 3.</p>
<table>
<caption><span>Table 3. Susceptibility Test Result Interpretive Criteria for Amoxicillin/Clavulanate Potassium</span></caption>
<col width="22%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<thead><tr class="First Last">
<th class="Botrule Lrule Toprule" align="center" valign="top"> Pathogen</th>
<th class="Lrule Toprule" align="center" colspan="3" valign="top"> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentration</span><br> (mcg/mL)</th>
<th class="Lrule Rrule Toprule" align="center" colspan="3" valign="top"> Disk Diffusion<br> (Zone Diameter in mm)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" valign="top">Â <span class="Bold">Pathogen</span>
</td>
<td class="Lrule" align="center" valign="top">Â <span class="Bold">S</span>
</td>
<td class="Lrule" align="center" valign="top">Â <span class="Bold">I</span>
</td>
<td class="Lrule" align="center" valign="top">Â <span class="Bold">R</span>
</td>
<td class="Lrule" align="center" valign="top">Â <span class="Bold">S</span>
</td>
<td class="Lrule" align="center" valign="top">Â <span class="Bold">I</span>
</td>
<td class="Lrule Rrule" align="center" valign="top">Â <span class="Bold">R</span>
</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">Streptococcus pneumoniae </span><br>(non-<span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> isolates)</td>
<td class="Lrule" align="center" valign="top">Â â‰¤ 2/1</td>
<td class="Lrule" align="center" valign="top">Â 4/2</td>
<td class="Lrule" align="center" valign="top">Â â‰¥ 8/4</td>
<td class="Lrule Rrule" align="center" colspan="3" valign="top">Â Not Applicable (NA)</td>
</tr>
<tr class="Last">
<td class="Lrule" valign="top">Â <span class="Italics">Haemophilus influenzae</span>
</td>
<td class="Lrule" align="center" valign="top">Â â‰¤ 4/2</td>
<td class="Lrule" align="center" valign="top">Â NA</td>
<td class="Lrule" align="center" valign="top">Â â‰¥ 8/4</td>
<td class="Lrule" align="center" valign="top">Â â‰¥ 20</td>
<td class="Lrule" align="center" valign="top">Â NA</td>
<td class="Lrule Rrule" align="center" colspan="3" valign="top">Â â‰¤ 19</td>
</tr>
</tbody>
</table>
<p><span class="Bold">NOTE:</span> Susceptibility of <span class="Italics">S.
                                    pneumoniae</span> should be determined using a 1-mcg oxacillin disk.
                                 Isolates with oxacillin zone sizes of â‰¥ 20 mm are susceptible to
                                 amoxicillin/clavulanic acid. An amoxicillin/clavulanic acid MIC
                                 should be determined on isolates of <span class="Italics">S. pneumoniae</span> with oxacillin
                                 zone sizes of â‰¤ 19 mm. </p>
<p><span class="Bold">NOTE:</span>
                                 Î²-lactamaseâ€“negative, ampicillin-resistant <span class="Italics">H. influenzae</span> isolates must be
                                 considered resistant to amoxicillin/clavulanic acid.</p>
<br><p> A report of S (â€œSusceptibleâ€?) indicates that the
                                 antimicrobial is likely to inhibit growth of the pathogen if the
                                 antimicrobial compound in the blood reaches the concentration
                                 usually achievable. A report of I (â€œIntermediateâ€?) indicates that
                                 the result should be considered equivocal, and, if the
                                 microorganism is not fully susceptible to alternative, clinically
                                 feasible antimicrobials, the test should be repeated. This category
                                 implies possible clinical applicability in body sites where the
                                 drug is physiologically concentrated or in situations where high
                                 doses of antimicrobial can be used. This category also provides a
                                 buffer zone that prevents small uncontrolled technical factors from
                                 causing major discrepancies in interpretation. A report of R
                                 (â€œResistantâ€?) indicates that the antimicrobial is not likely to
                                 inhibit growth of the pathogen if the antimicrobial compound in the
                                 blood reaches the concentration usually achievable; other therapy
                                 should be selected.</p>
<p> Standardized susceptibility test procedures require the
                                 use of quality control microorganisms to determine the performance
                                 of the test procedures.<span class="Sup">1-3</span> Standard amoxicillin/clavulanate
                                 potassium powder should provide the MIC ranges for the quality
                                 control organisms in Table 4. For the disk diffusion technique, the
                                 30 mcg-amoxicillin/clavulanate potassium disk should provide the
                                 zone diameter ranges for the quality control organisms in Table
                              4.</p>
<table>
<caption><span>Table 4. Acceptable Quality Control Ranges for Amoxicillin/Clavulanate Potassium</span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<th class="Lrule Toprule" valign="bottom"> Quality Control Organism</th>
<th class="Lrule Toprule" align="center" valign="top"> Minimum Inhibitory <br>Concentration Range<br>(mcg/mL)</th>
<th class="Lrule Rrule Toprule" align="center" valign="top"> Disk Diffusion<br>(Zone Diameter<br>Range in mm)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>ATCC is a trademark of the American Type Culture
                                             Collection.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€ </a></dt>
<dd>When using <span class="Italics">Haemophilus</span> Test Medium (HTM).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" valign="top">Â <span class="Italics">Escherichia coli </span>ATCC<span class="Sup">Â®</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> 35218
                                          <a name="footnote-reference-3" href="#footnote-3" class="Sup">â€ </a><br>(H. influenzae quality control)</td>
<td class="Lrule" align="center" valign="top">Â 4/2 to 16/8</td>
<td class="Lrule Rrule" align="center" valign="top">Â 17 to 22</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">Haemophilus influenzae</span> ATCC 49247</td>
<td class="Lrule" align="center" valign="top">Â 2/1 to 16/8</td>
<td class="Lrule Rrule" align="center" valign="top">Â 15 to 23</td>
</tr>
<tr class="Last">
<td class="Lrule" valign="top">Â <span class="Italics">Streptococcus pneumoniae</span> ATCC 49619</td>
<td class="Lrule" align="center" valign="top">Â 0.03/0.016 to 0.12/0.06</td>
<td class="Lrule Rrule" align="center" valign="top">Â NA</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_baa2b5fc-4f3b-4d53-8b73-596109b9a059"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL is
                     indicated for the treatment of pediatric patients with recurrent or persistent
                     acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> due to <span class="Italics">S. pneumoniae</span>
                     (penicillin MICs â‰¤ 2 mcg/mL), <span class="Italics">H.
                        influenzae</span> (including Î²-lactamaseâ€“producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), or <br><span class="Italics">M. catarrhalis</span> (including
                     Î²-lactamaseâ€“producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) characterized by the following risk
                     factors:</p>
<ul class="Disk"><li>antibiotic exposure for acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> within the preceding 3 months, and either of the following:
                     <ul class="Circle">
<li>age â‰¤ 2 years</li>
<li>daycare attendance</li>
</ul>
</li></ul>
<p>[See <a href="#LINK_d0452769-1b11-4af0-b8c6-842d66d86f5d">CLINICAL PHARMACOLOGY</a>, <a href="#LINK_1e6ccf23-de9f-4b45-bc21-de34225b5c2b">Microbiology</a>.]</p>
<p><span class="Bold">NOTE:</span> Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> due to <span class="Italics">S. pneumoniae</span> alone can be treated with
                     amoxicillin. Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL is not
                     indicated for the treatment of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> due to <span class="Italics">S. pneumoniae</span> with penicillin MIC â‰¥
                     4 mcg/mL.</p>
<p>Therapy may be instituted prior to obtaining the results from
                     bacteriological studies when there is reason to believe the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may
                     involve both <span class="Italics">S. pneumoniae</span> (penicillin
                     MIC â‰¤ 2 mcg/mL) and the Î²-lactamaseâ€“producing organisms listed
                     above.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the
                     effectiveness of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL
                     and other antibacterial drugs, Amoxicillin and Clavulanate Potassium 600
                     mg/42.9 mg per 5 mL should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are
                     proven or strongly suspected to be caused by susceptible bacteria. When culture
                     and susceptibility information are available, they should be considered in
                     selecting or modifying antibacterial therapy. In the absence of such data,
                     local epidemiology and susceptibility patterns may contribute to the empiric
                     selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_405aa545-5186-4efa-b076-9db644042933"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to any penicillin. It is also contraindicated in patients with a previous history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/hepatic dysfunction associated with AMOXICILLIN AND CLAVULANATE POTASSIUM.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_761db988-f610-43ea-8421-c25d796edc42"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"> SERIOUS AND OCCASIONALLY FATAL <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> (ANAPHYLACTIC)
                     REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. THESE REACTIONS
                     ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN
                     <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE
                     HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span>
                     WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE
                     INITIATING THERAPY WITH AMOXICILLIN AND CLAVULANATE POTASSIUM 600 MG/42.9 MG PER 5 ML, CAREFUL INQUIRY SHOULD BE MADE
                     CONCERNING PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO PENICILLINS, CEPHALOSPORINS,
                     OR OTHER ALLERGENS. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> OCCURS, AMOXICILLIN AND CLAVULANATE POTASSIUM 600 MG/42.9 MG PER 5 ML SHOULD BE
                     DISCONTINUED AND THE APPROPRIATE THERAPY INSTITUTED. <span class="Bold">SERIOUS ANAPHYLACTIC
                     REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN,
                     INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO
                        BE ADMINISTERED AS INDICATED.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with
                        nearly all antibacterial agents, including amoxicillin/clavulanate
                        potassium, and has ranged in severity from mild to life-threatening.
                        Therefore, it is important to consider this diagnosis in patients who
                        present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of antibacterial
                        agents.</span></p>
<p> Treatment with antibacterial agents alters the normal flora of the
                     colon and may permit overgrowth of clostridia. Studies indicate that a toxin
                     produced by <span class="Italics">Clostridium difficile</span> is one primary cause of
                     â€œantibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.â€? </p>
<p>After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established,
                     appropriate therapeutic measures should be initiated. Mild cases of
                     <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. In
                     moderate to severe cases, consideration should be given to management with
                     fluids and electrolytes, protein supplementation, and treatment with an
                     antibacterial drug clinically effective against <span class="Italics">C. difficile
                        <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</span></p>
<p>Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL should be used with caution in patients with evidence
                     of hepatic dysfunction. Hepatic toxicity associated with the use of
                     amoxicillin/clavulanate potassium is usually reversible. On rare occasions,
                     <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported (less than 1 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> reported per estimated 4 million
                     prescriptions worldwide). These have generally been cases associated with
                     serious underlying diseases or concomitant medications. (See <a href="#LINK_405aa545-5186-4efa-b076-9db644042933">CONTRAINDICATIONS</a>
                     and <a href="#LINK_acdad055-f9e5-49c9-bdbf-b9deae7172dc">ADVERSE REACTIONSâ€”Liver</a>.)</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_989e6e1b-9690-41bc-b1a1-b41d2a0edbc8"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_e7cc6662-6365-48cc-82a5-e9259805fad6"></a><a name="section-7.1"></a><p></p>
<h2>General:</h2>
<p class="First">While amoxicillin/clavulanate possesses the characteristic low
                           toxicity of the penicillin group of antibiotics, periodic assessment of
                           organ system functions, including renal, hepatic, and hematopoietic
                           function, is advisable if therapy is for longer than the drug is approved
                           for administration.</p>
<p>A high percentage of patients with mononucleosis who receive
                           ampicillin develop an erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. Thus, ampicillin-class
                           antibiotics should not be administered to patients with mononucleosis.</p>
<p>The possibility of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> with mycotic or bacterial
                           pathogens should be kept in mind during therapy. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> occur
                           (usually involving <span class="Italics">Pseudomonas </span> or
                              <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span>), the drug should be
                           discontinued and/or appropriate therapy instituted.</p>
<p>Prescribing Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL in the absence of a proven or strongly
                           suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to
                           provide benefit to the patient and increases the risk of the development
                           of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_c846fb32-1ae1-4dec-8b95-67f78f8890a5"></a><a name="section-7.2"></a><p></p>
<h2>Information for the Patient:</h2>
<p class="First">Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL should be taken every 12 hours with a meal or
                           snack to reduce the possibility of <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal upset</span>. If <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
                           develops and is severe or lasts more than 2 or 3 days, call your
                        doctor.</p>
<p> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually
                           ends when the antibiotic is discontinued. Sometimes after starting
                           treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span>
                           (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as 2 or more
                           months after having taken the last dose of the antibiotic. If this
                           occurs, patients should contact their physician as soon as
                        possible.</p>
<p>Keep suspension refrigerated. Shake well before using. When
                           dosing a child with the suspension (liquid) of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL, use a
                           dosing spoon or medicine dropper. Be sure to rinse the spoon or dropper
                           after each use. Bottles of suspension of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL  may contain
                           more liquid than required. Follow your doctorâ€™s instructions about the
                           amount to use and the days of treatment your child requires. Discard any
                           unused medicine.</p>
<p>Patients should be counseled that antibacterial drugs, including
                           Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They
                           do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told
                           that although it is common to feel better early in the course of therapy,
                           the medication should be taken exactly as directed. Skipping doses or not
                           completing the full course of therapy may: (1) decrease the effectiveness
                           of the immediate treatment, and (2) increase the likelihood that bacteria
                           will develop resistance and will not be treatable by Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL or
                           other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9c2a3f3e-3a33-48c6-bb98-d1a599efabbe"></a><a name="section-7.3"></a><p></p>
<h2>Phenylketonurics:</h2>
<p class="First">Each 5 mL of the 600 mg/42.9 mg per 5 mL suspension of Amoxicillin and Clavulanate Potassium
                           contains 7 mg phenylalanine.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_7b59eac7-fec0-4702-bb45-801167ed95e0"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Probenecid decreases the renal tubular secretion of amoxicillin.
                           Concurrent use with Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL may result in increased and
                           prolonged blood levels of amoxicillin. Co-administration of probenecid
                           cannot be recommended.</p>
<p>Abnormal prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (increased
                           international normalized ratio [INR]) has been reported rarely in
                           patients receiving amoxicillin and oral anticoagulants. Appropriate
                           monitoring should be undertaken when anticoagulants are prescribed
                           concurrently. Adjustments in the dose of oral anticoagulants may be
                           necessary to maintain the desired level of anticoagulation.</p>
<p>The concurrent administration of allopurinol and ampicillin
                           increases substantially the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> in patients receiving
                           both drugs as compared to patients receiving ampicillin alone. It is not
                           known whether this potentiation of ampicillin <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> is due to
                           allopurinol or the <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> present in these patients. There are no
                           data with Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL and allopurinol administered concurrently.</p>
<p>In common with other broad-spectrum antibiotics, amoxicillin/clavulanate may reduce the efficacy of oral contraceptives.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_fb343b44-13e2-4491-b724-56e94c86d2a8"></a><a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions:</h2>
<p class="First">Oral administration of AMOXICILLIN AND CLAVULANATE POTASSIUM will result in high urine
                           concentrations of amoxicillin. High urine concentrations of ampicillin
                           may result in false-positive reactions when testing for the presence of
                           glucose in urine using CLINITEST<span class="Sup">Â®</span>, Benedictâ€™s Solution, or
                           Fehlingâ€™s Solution. Since this effect may also occur with amoxicillin and
                           therefore Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL, it is recommended that glucose tests based on
                           enzymatic glucose oxidase reactions (such as CLINISTIX<span class="Sup">Â®</span>) be
                           used.</p>
<p>Following administration of ampicillin to pregnant women, a
                           transient decrease in plasma concentration of total conjugated estriol,
                           estriol-glucuronide, conjugated estrone, and estradiol has been noted.
                           This effect may also occur with amoxicillin and therefore
                           Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_c1725e1b-aaf6-4451-b760-9ff167044ce5"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First"> Long-term studies in animals have not been performed to evaluate
                           carcinogenic potential. The mutagenic potential of AMOXICILLIN AND CLAVULANATE POTASSIUM was
                           investigated in vitro with an Ames test, a human lymphocyte cytogenetic
                           assay, a yeast test, and a mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay, and in
                           vivo with mouse micronucleus tests and a dominant lethal test. All were
                           negative apart from the in vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay where weak activity
                           was found at very high, cytotoxic concentrations. AMOXICILLIN AND CLAVULANATE POTASSIUM at oral doses
                           of up to 1,200 mg/kg/day (5.7 times the maximum adult human dose based on
                           body surface area) was found to have no effect on fertility and
                           reproductive performance in rats, dosed with a 2:1 ratio formulation of
                           amoxicillin:clavulanate.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_c08ee835-9c79-4e49-821f-9769799285e0"></a><a name="section-7.7"></a><p></p>
<h2>Teratogenic Effects:
</h2>
<p class="First">Pregnancy (Category B). Reproduction studies performed in
                                 pregnant rats and mice given AMOXICILLIN AND CLAVULANATE POTASSIUM at oral dosages up to 1,200
                                 mg/kg/day (4.9 and 2.8 times the maximum adult human oral dose
                                 based on body surface area, respectively), revealed no evidence of
                                 harm to the fetus due to AMOXICILLIN AND CLAVULANATE POTASSIUM. There are, however, no adequate
                                 and well-controlled studies in pregnant women. Because animal
                                 reproduction studies are not always predictive of human response,
                                 this drug should be used during pregnancy only if clearly
                              needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_d865913d-9a87-45c6-9c74-a98606373f25"></a><a name="section-7.8"></a><p></p>
<h2>
                                 Labor and Delivery:
</h2>
<p class="First">Oral ampicillin-class antibiotics are generally poorly
                                 absorbed during labor. Studies in guinea pigs have shown that
                                 intravenous administration of ampicillin decreased the uterine
                                 tone, frequency of contractions, height of contractions, and
                                 duration of contractions. However, it is not known whether the use
                                 of AMOXICILLIN AND CLAVULANATE POTASSIUM in humans during labor or delivery has immediate or
                                 delayed adverse effects on the fetus, prolongs the duration of
                                 labor, or increases the likelihood that forceps delivery or other
                                 obstetrical intervention or resuscitation of the newborn will be
                                 necessary. In a single study in women with premature rupture of
                                 fetal membranes, it was reported that <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment with
                                 AMOXICILLIN AND CLAVULANATE POTASSIUM may be associated with an increased risk of necrotizing
                                 <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> in neonates.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_bf01cbb4-08e6-4f08-ba33-4deff07117aa"></a><a name="section-7.9"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Ampicillin-class antibiotics are excreted in human milk;
                           therefore, caution should be exercised when AMOXICILLIN AND CLAVULANATE POTASSIUM is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_97d78c0b-933f-4a45-a233-8b9670b924f5"></a><a name="section-7.10"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Safety and efficacy of  Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL in infants younger than 3
                                 months have not been established. Safety and efficacy of  Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL
                           have been demonstrated for treatment of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> in infants and
                                 children 3 months to 12 years (see <a href="#LINK_9fe80d29-86cd-43ba-85ad-f43bf45293f5">Description of Clinical
                                    Studies</a>).</p>
<p>The safety and effectiveness of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL have been
                           established for the treatment of pediatric patients (3 months to 12
                           years) with acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>. This use is supported by evidence
                                 from adequate and well-controlled studies of AMOXICILLIN AND CLAVULANATE POTASSIUM Extended
                           Release Tablets in adults with acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, studies of
                                 Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL in pediatric patients with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, and by
                           similar pharmacokinetics of amoxicillin and clavulanate in pediatric
                                 patients taking Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL (see <a href="#LINK_d0452769-1b11-4af0-b8c6-842d66d86f5d">CLINICAL PHARMACOLOGY</a>) and adults
                                 taking AMOXICILLIN AND CLAVULANATE POTASSIUM Extended Release Tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_4828f919-5974-4f63-91ba-58174ba8ecd2"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL is generally well tolerated. The majority of side
                     effects observed in pediatric clinical trials of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> were either
                     mild or moderate, and transient in nature; 4.4% of patients discontinued
                     therapy because of drug-related side effects. The most commonly reported side
                     effects with probable or suspected relationship to Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL were
                     <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, i.e., <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> (3.5%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.9%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2.2%),
                     <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> (1.4%), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1.1%). The most common adverse experiences leading
                     to withdrawal that were of probable or suspected relationship to Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.5%) and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1.4%).</p>
<p>The following adverse reactions have been reported for ampicillin-class antibiotics:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_89e94dd4-df81-437a-9914-ff9642a324fc"></a><a name="section-8.1"></a><p></p>
<h2>Gastrointestinal:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>,
                           <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, black â€œhairyâ€? tongue, <span class="product-label-link" type="condition" conceptid="4104522" conceptname="Mucocutaneous candidiasis">mucocutaneous candidiasis</span>,
                           <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, and hemorrhagic/<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>. Onset of
                           <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic
                           treatment. (See <a href="#LINK_761db988-f610-43ea-8421-c25d796edc42">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3ae7f681-e25e-453e-bc50-1d0cd00508c5"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, serum sicknessâˆ’like
                           reactions (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>,
                           <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and frequently <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>), <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (rarely
                           <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>), <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>,
                           and an occasional case of exfoliative
                           <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> (including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) have been reported.
                           These reactions may be controlled with antihistamines and, if necessary,
                           systemic corticosteroids. Whenever such reactions occur, the drug should
                           be discontinued, unless the opinion of the physician dictates otherwise.
                           Serious and occasional fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions
                           can occur with oral penicillin. (See <a href="#LINK_761db988-f610-43ea-8421-c25d796edc42">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_acdad055-f9e5-49c9-bdbf-b9deae7172dc"></a><a name="section-8.3"></a><p></p>
<h2>Liver:</h2>
<p class="First">A moderate rise in AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) and/or ALT (SGPT) has been noted in
                           patients treated with ampicillin-class antibiotics, but the significance
                           of these findings is unknown. Hepatic dysfunction, including increases in serum
                           transaminases (AST and/or ALT), serum bilirubin, and/or alkaline
                           phosphatase, has been infrequently reported with AMOXICILLIN AND CLAVULANATE POTASSIUM. It has been
                           reported more commonly in the elderly, in males, or in patients on
                           prolonged treatment. The histologic findings on liver biopsy have
                           consisted of predominantly cholestatic, hepatocellular, or mixed
                           cholestatic-hepatocellular changes. The onset of signs/symptoms of
                           hepatic dysfunction may occur during or several weeks after therapy has
                           been discontinued. The hepatic dysfunction, which may be severe, is
                           usually reversible. On rare occasions, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported (less
                           than 1 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> reported per estimated 4 million prescriptions worldwide).
                           These have generally been cases associated with serious underlying
                           diseases or concomitant medications. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_09238ab1-c65b-4dee-b7c5-c7aa5836372f"></a><a name="section-8.4"></a><p></p>
<h2>Renal:</h2>
<p class="First">Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> have been reported rarely.
                           <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span> has also been reported (see <span class="Bold">OVERDOSAGE</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ae90dca2-4c03-4b81-bab1-5136e4cb5051"></a><a name="section-8.5"></a><p></p>
<h2>Hemic and Lymphatic Systems:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, including <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>,
                           <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>
                           have been reported during therapy with penicillins. These reactions are
                           usually reversible on discontinuation of therapy and are believed to be
                           <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> phenomena. A slight <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span> was noted in less
                           than 1% of the patients treated with AMOXICILLIN AND CLAVULANATE POTASSIUM. There have been reports
                           of increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving AMOXICILLIN AND CLAVULANATE POTASSIUM and
                           anticoagulant therapy concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_85917a54-99e0-4d50-9ed5-096eacbe5d25"></a><a name="section-8.6"></a><p></p>
<h2>Central Nervous System:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, behavioral changes, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>,
                           <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and reversible <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> have been reported
                           rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_12c89fa2-a043-4103-a2de-2956d646b3a1"></a><a name="section-8.7"></a><p></p>
<h2>Miscellaneous:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="45757361" conceptname="Mottled teeth">Tooth discoloration</span> (brown, yellow, or gray staining) has been
                           rarely reported. Most reports occurred in pediatric patients.
                           Discoloration was reduced or eliminated with brushing or dental cleaning
                           in most cases.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_fd4deb9a-acfe-45e8-859c-7962641886f8"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Following overdosage, patients have experienced primarily
                     <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> including stomach and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and
                     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> have also been observed in a small
                     number of patients.</p>
<p>In the case of overdosage, discontinue Amoxicillin and Clavulanate
                     Potassium 600 mg/42.9 mg per 5 mL, treat
                     symptomatically, and institute supportive measures as required. If the
                     overdosage is very recent and there is no contraindication, an attempt at
                     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or other means of removal of drug from the stomach may be performed. A
                     prospective study of 51 pediatric patients at a poison control center suggested that
                     overdosages of less than 250Â mg/kg of amoxicillin are not associated with
                     significant clinical symptoms and do not require gastric emptying.<span class="Sup">4</span></p>
<p>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> resulting in oliguric <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> has been
                     reported in a small number of patients after overdosage with amoxicillin.</p>
<p><span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span>, in some cases leading to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, has also been
                     reported after amoxicillin overdosage in adult and pediatric patients. In case
                     of overdosage, adequate fluid intake and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> should be maintained to
                     reduce the risk of amoxicillin <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> appears to be reversible with cessation of drug
                     administration. High blood levels may occur more readily in patients with
                     <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> because of decreased renal clearance of both
                     amoxicillin and clavulanate. Both amoxicillin and clavulanate are removed from
                     the circulation by hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_60c28869-5d0b-49c4-b48d-ca1721d49ffb"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Amoxicillin and Clavulanate Potassium, 600 mg/42.9 mg per 5 mL, does not
                     contain the same amount of clavulanic acid (as the potassium salt) as any
                     of the other suspensions of AMOXICILLIN AND CLAVULANATE POTASSIUM. Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL contains
                     42.9 mg of clavulanic acid per 5 mL, whereas the 200 mg/5 mL suspension
                     of AMOXICILLIN  AND CLAVULANATE  POTASSIUM  contains  28.5 mg of
                     clavulanic acid per 5 mL and the 400 mg/5 mL suspension contains 57 mg
                     of clavulanic acid per 5 mL. Therefore, the 200 mg/28.5 mg/5 mL and 400
                     mg/57 mg/5 mL  suspensions   of  AMOXICILLIN   AND CLAVULANATE
                     POTASSIUM  should <span class="Italics">not</span> be substituted  for Amoxicillin  and Clavulanate
                     Potassium 600 mg/42.9 mg per 5 mL as they are not interchangeable.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f2784b3e-b47e-4088-a02d-03c892c77bf7"></a><a name="section-10.1"></a><p></p>
<h2>Dosage:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e0fef97f-6145-4800-aec7-23f7acc8327d"></a><a name="section-10.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Pediatric patients 3 months and older:</span></span></h3>
<p class="First">Based on the amoxicillin component (600 mg/5 mL), the recommended
                           dose of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL is
                           90 mg/kg/day divided every 12 hours, administered for 10 days (see chart
                           below).</p>
<table>
<col>
<col>
<thead><tr class="First Last">
<th class="Lrule Toprule" align="center" valign="bottom"> Body Weight (kg)</th>
<th class="Lrule Rrule Toprule" align="center" valign="top"> Volume of  Amoxicillin and Clavulanate Potassium<br>
                                    600 mg/42.9 mg per 5 mL<br>
                                    providing 90 mg/kg/day
                                 </th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="center" valign="top">Â 8</td>
<td class="Lrule Rrule" align="center" valign="top">Â 3.0 mL twice daily</td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">Â 12</td>
<td class="Lrule Rrule" align="center" valign="top">Â 4.5 mL twice daily</td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">Â 16</td>
<td class="Lrule Rrule" align="center" valign="top">Â 6.0 mL twice daily</td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">Â 20</td>
<td class="Lrule Rrule" align="center" valign="top">Â 7.5 mL twice daily</td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">Â 24</td>
<td class="Lrule Rrule" align="center" valign="top">Â 9.0 mL twice daily</td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">Â 28</td>
<td class="Lrule Rrule" align="center" valign="top">Â 10.5 mL twice daily</td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">Â 32</td>
<td class="Lrule Rrule" align="center" valign="top">Â 12.0 mL twice daily</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center" valign="top">Â 36</td>
<td class="Lrule Rrule" align="center" valign="top">Â 13.5 mL twice daily</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_07d9000a-79cc-48ce-9cef-9646b43539f7"></a><a name="section-10.1.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Pediatric patients weighing 40 kg and more:
                              </span></span></h3>
<p class="First">Experience with Amoxicillin  and
                                 Clavulanate Potassium (600 mg/5 mL formulation) in this group is not available.
                              </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d27a8f6b-f11d-47b2-add6-6401be23ad0c"></a><a name="section-10.1.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Adults:</span></span></h3>
<p class="First">Experience with Amoxicillin and Clavulanate Potassium (600
                                 mg/5 mL formulation) in adults is not available and adults who have
                                 difficulty swallowing should not be given Amoxicillin and
                                 Clavulanate Potassium (600 mg/5 mL) in place of the 500-mg or
                                 875-mg tablet of AMOXICILLIN AND CLAVULANATE POTASSIUM.</p>
<p>Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals. (See <a href="#LINK_761db988-f610-43ea-8421-c25d796edc42">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1b2e7d90-7370-4eed-88d8-3bd4d202d6d8"></a><a name="section-10.1.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Directions for Mixing Oral Suspension:</span></span></h3>
<p class="First">Prepare a suspension at time of dispensing as follows: Tap bottle
                           until all the powder flows freely. Add approximately 2/3 of the total
                           amount of water for reconstitution (see table below) and shake vigorously
                           to suspend powder. Add remainder of the water and again shake vigorously.</p>
<table>
<caption><span>Amoxicillin and Clavulanate Potassium (600 mg/5 mL Suspension)</span></caption>
<col width="29.0%">
<col width="71.0%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="bottom">Â Bottle Size</td>
<td class="Toprule" align="center" valign="top">Â  Amount of Water<br>Required for Reconstitution</td>
</tr>
<tr>
<td align="center" valign="top">Â 75Â mL</td>
<td align="center" valign="top">Â 70Â mL</td>
</tr>
<tr>
<td align="center" valign="top">Â 125Â mL</td>
<td align="center" valign="top">Â 110Â mL</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">Â 200Â mL</td>
<td class="Botrule" align="center" valign="top">Â 180Â mL</td>
</tr>
</tbody>
</table>
<p>Each teaspoonful (5 mL) will contain 600 mg amoxicillin as the trihydrate and 42.9
                           mg of clavulanic acid as the potassium salt.
                        </p>
<p><span class="Bold">NOTE:</span> SHAKE ORAL SUSPENSION WELL BEFORE USING.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_586eb181-ff07-42e7-b0b9-5a63519f8136"></a><a name="section-10.2"></a><p></p>
<h2>Information for the Pharmacist:</h2>
<p class="First">For patients who wish to alter the taste of Amoxicillin and
                           Clavulanate Potassium 600 mg/42.9 mg per 5 mL, immediately after
                           reconstitution 1 drop of FLAVORx<span class="Sup">â„¢</span> (apple, banana cream, bubble gum,
                           cherry, or watermelon flavor) may be added for every 5 mL of Amoxicillin
                           and Clavulanate Potassium 600 mg/42.9 mg per 5 mL. The resulting
                           suspension is stable for 10 days under refrigeration. Stability of
                           Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL when mixed
                           with other flavors distributed by FLAVORx has not been evaluated for
                           flavors other than the 5 flavors listed above.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_96b49bb6-96c9-4bc0-99de-2a14fb363ed3"></a><a name="section-10.3"></a><p></p>
<h2>Administration:</h2>
<p class="First">To minimize the potential for gastrointestinal intolerance,
                           Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL should be
                           taken at the start of a meal. Absorption of clavulanate potassium may be
                           enhanced when Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5
                           mL is administered at the start of a meal.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_535fb7de-ccd4-4508-937a-9bbdaf284413"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Amoxicillin and Clavulanate  Potassium, 600 mg/5  mL, for Oral Suspension:</span>
                     Each 5 mL of reconstituted strawberry cream-flavored suspension contains 600
                     mg amoxicillin and 42.9 mg clavulanic acid as the potassium salt.</p>
<p><span class="Bold">HOW SUPPLIED</span></p>
<p>NDC 33261-0970-01Â Â Â Â Â 200Â mL bottle</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_d6cdedc1-b82e-4fcf-9fed-961b9768846a"></a><a name="section-12"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Store reconstituted suspension under refrigeration. Discard unused suspension
                     after 10 days. Store dry powder for oral suspension at or below 25Â°C (77Â°F).
                     Dispense in original container.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_9fe80d29-86cd-43ba-85ad-f43bf45293f5"></a><a name="section-13"></a><p></p>
<h1>Description of Clinical Studies</h1>
<p class="First">Two clinical studies were conducted in pediatric patients with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>.</p>
<p>A non-comparative, open-label study assessed the bacteriologic and
                     clinical efficacy of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5
                     mL (90/6.4 mg/kg/day, divided every 12 hours) for 10 days in 521 pediatric
                     patients (3 to 50 months) with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. The primary objective was to
                     assess bacteriological response in children with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> due to <span class="Italics">S.
                        pneumoniae</span> with amoxicillin/clavulanic acid MICs of 4 mcg/mL. The study sought
                     the enrollment of patients with the following risk factors: Failure of
                     antibiotic therapy for acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> in the previous 3 months, history of
                     recurrent episodes of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, â‰¤ 2 years, or daycare attendance.
                     Prior to receiving Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5
                     mL, all patients had tympanocentesis to obtain middle ear fluid for
                     bacteriological evaluation. Patients from whom <span class="Italics">S. pneumoniae</span> (alone or in
                     combination with other bacteria) was isolated had a second tympanocentesis 4 to
                     6 days after the start of therapy. Clinical assessments were planned for all
                     patients during treatment (4-6 days after starting therapy), as well as 2-4
                     days post-treatment and 15-18 days post-treatment. Bacteriological success was
                     defined as the absence of the pretreatment pathogen from the on-therapy
                     tympanocentesis specimen. Clinical success was defined as improvement or
                     resolution of signs and symptoms. Clinical failure was defined as lack of
                     improvement or worsening of signs and/or symptoms at any time following at
                     least 72 hours of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5
                     mL; patients who received an additional systemic antibacterial drug for <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>
                     media after 3 days of therapy were considered clinical failures.
                     Bacteriological eradication on therapy (day 4-6 visit) in the per protocol
                     population is summarized in the following table: </p>
<table>
<caption><span>Table 5. Bacteriologic Eradication Rates in the Per Protocol Population</span></caption>
<col width="35%">
<col width="20%">
<col width="20%">
<col width="25%">
<thead><tr class="First Last">
<th class="Lrule Toprule" valign="top"></th>
<th class="Lrule Rrule Toprule" align="center" colspan="3" valign="top"> Bacteriologic Eradication on Therapy</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>CI = confidence intervals; 95% CIs are not adjusted for multiple comparisons.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" valign="top">Â <span class="Bold">Pathogen</span>
</td>
<td class="Lrule" align="center" valign="top">Â <span class="Bold">n/N</span>
</td>
<td class="Lrule" align="center" valign="top">Â <span class="Bold">%</span>
</td>
<td class="Lrule Rrule" align="center" valign="top">Â <span class="Bold">95% CI</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â All S. pneumoniae</td>
<td class="Lrule" align="center" valign="top">Â 121/123</td>
<td class="Lrule" align="center" valign="top">Â 98.4</td>
<td class="Lrule Rrule" align="center" valign="top">Â (94.3, 99.8)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">S. pneumoniae</span> with penicillin<br>MIC = 2 mcg/mL</td>
<td class="Lrule" align="center" valign="top">Â 19/19</td>
<td class="Lrule" align="center" valign="top">Â 100</td>
<td class="Lrule Rrule" align="center" valign="top">Â (82.4, 100.0)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">S. pneumoniae</span> with penicillin<br>MIC = 4 mcg/mL</td>
<td class="Lrule" align="center" valign="top">Â 12/14</td>
<td class="Lrule" align="center" valign="top">Â 85.7</td>
<td class="Lrule Rrule" align="center" valign="top">Â (57.2, 98.2)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">H. influenzae</span>
</td>
<td class="Lrule" align="center" valign="top">Â 75/81</td>
<td class="Lrule" align="center" valign="top">Â 92.6</td>
<td class="Lrule Rrule" align="center" valign="top">Â (84.6, 97.2)</td>
</tr>
<tr class="Last">
<td class="Lrule" valign="top">Â <span class="Italics">M. catarrhalis</span>
</td>
<td class="Lrule" align="center" valign="top">Â 11/11</td>
<td class="Lrule" align="center" valign="top">Â 100</td>
<td class="Lrule Rrule" align="center" valign="top">Â (71.5, 100.0)</td>
</tr>
</tbody>
</table>
<p>Clinical assessments were made in the per protocol population 2-4 days
                     post-therapy and 15-18 days post-therapy. Patients who responded to therapy 2-4
                     days post-therapy were followed for 15-18 days post-therapy to assess them for
                     acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. Nonresponders at 2-4 days post-therapy were considered
                     failures at the latter timepoint.</p>
<table>
<caption><span>Table 6. Clinical Assessments in the Per Protocol Population (Includes S. pneumoniae Patients With Penicillin MICs = 2 or 4 mcg/mL<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>)
                     </span></caption>
<col width="35%">
<col width="20%">
<col width="20%">
<col width="25%">
<thead><tr class="First Last">
<th class="Lrule Toprule" valign="top"></th>
<th class="Lrule Rrule Toprule" align="center" colspan="3" valign="top"> 2-4 Days Post-Therapy (Primary Endpoint)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>
<span class="Italics">S. pneumoniae</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> with penicillin MICs of 2 or 4 mcg/mL  are considered resistant to penicillin.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">â€ </a></dt>
<dd>CI = confidence intervals; 95% CIs are not adjusted for multiple comparisons.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">â€¡</a></dt>
<dd>Clinical assessments at 15-18  days post-therapy may have been confounded by <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>  and  new episodes  of acute  <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>  with time elapsed post-treatment.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" valign="top">Â <span class="Bold">Pathogen</span>
</td>
<td class="Lrule" align="center" valign="top">Â <span class="Bold">n/N</span>
</td>
<td class="Lrule" align="center" valign="top">Â <span class="Bold">%</span>
</td>
<td class="Lrule Rrule" align="center" valign="top">Â <span class="Bold">95% CI</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">â€ </a>
</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â All <span class="Italics">S. pneumoniae</span>
</td>
<td class="Lrule" align="center" valign="top">Â 122/137</td>
<td class="Lrule" align="center" valign="top">Â 89.1</td>
<td class="Lrule Rrule" align="center" valign="top">Â (82.6, 93.7)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">S. pneumoniae</span> with penicillin<br>MIC = 2 mcg/mL</td>
<td class="Lrule" align="center" valign="top">Â 17/20</td>
<td class="Lrule" align="center" valign="top">Â 85.0</td>
<td class="Lrule Rrule" align="center" valign="top">Â (62.1, 96.8)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">S. pneumoniae</span> with penicillin<br>MIC = 4 mcg/mL</td>
<td class="Lrule" align="center" valign="top">Â 11/14</td>
<td class="Lrule" align="center" valign="top">Â 78.6</td>
<td class="Lrule Rrule" align="center" valign="top">Â (49.2, 95.3)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">H. influenzae</span>
</td>
<td class="Lrule" align="center" valign="top">Â 141/162</td>
<td class="Lrule" align="center" valign="top">Â 87.0</td>
<td class="Lrule Rrule" align="center" valign="top">Â (80.9, 91.8)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">M. catarrhalis</span>
</td>
<td class="Lrule" align="center" valign="top">Â 22/26</td>
<td class="Lrule" align="center" valign="top">Â 84.6</td>
<td class="Lrule Rrule" align="center" valign="top">Â (65.1, 95.6)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â </td>
<td class="Botrule" align="center" valign="top">Â </td>
<td class="Botrule" align="center" valign="top">Â </td>
<td class="Rrule" align="center" valign="top">Â </td>
</tr>
<tr>
<th class="Lrule" valign="top"></th>
<th class="Lrule Rrule" align="center" colspan="3" valign="top"> 15-18 Days Post-Therapy<a name="footnote-reference-7" href="#footnote-7" class="Sup">â€¡</a> (Secondary Endpoint)</th>
</tr>
<tr>
<td class="Lrule Toprule" valign="top">Â <span class="Bold">Pathogen</span>
</td>
<td class="Lrule Toprule" align="center" valign="top">Â <span class="Bold">n/N</span>
</td>
<td class="Lrule Toprule" align="center" valign="top">Â <span class="Bold">%</span>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">Â <span class="Bold">95% CI</span>
</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â All <span class="Italics">S. pneumoniae</span>
</td>
<td class="Lrule" align="center" valign="top">Â 95/136</td>
<td class="Lrule" align="center" valign="top">Â 69.9</td>
<td class="Lrule Rrule" align="center" valign="top">Â (61.4, 77.4)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">S. pneumoniae</span> with penicillin<br>MIC = 2 mcg/mL</td>
<td class="Lrule" align="center" valign="top">Â 11/20</td>
<td class="Lrule" align="center" valign="top">Â 55.0</td>
<td class="Lrule Rrule" align="center" valign="top">Â (31.5, 76.9)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">S. pneumoniae</span> with penicillin<br>MIC = 4 mcg/mL</td>
<td class="Lrule" align="center" valign="top">Â 5/14</td>
<td class="Lrule" align="center" valign="top">Â 35.7</td>
<td class="Lrule Rrule" align="center" valign="top">Â (12.8, 64.9)</td>
</tr>
<tr>
<td class="Lrule" valign="top">Â <span class="Italics">H. influenzae</span>
</td>
<td class="Lrule" align="center" valign="top">Â 106/156</td>
<td class="Lrule" align="center" valign="top">Â 67.9</td>
<td class="Lrule Rrule" align="center" valign="top">Â (60.0, 75.2)</td>
</tr>
<tr class="Last">
<td class="Lrule" valign="top">Â <span class="Italics">M. catarrhalis</span>
</td>
<td class="Lrule" align="center" valign="top">Â 14/25</td>
<td class="Lrule" align="center" valign="top">Â 56.0</td>
<td class="Lrule Rrule" align="center" valign="top">Â (34.9, 75.6)</td>
</tr>
</tbody>
</table>
<p>In the intent-to-treat analysis, overall clinical outcomes at 2-4 days
                     and 15-18 days post-treatment in patients with <span class="Italics">S. pneumoniae</span> with penicillin
                     MIC = 2 mcg/mL and 4 mcg/mL were 29/41 (71%) and 17/41 (41.5%), respectively.
                  </p>
<p>In the intent-to-treat population of 521 patients, the most frequently
                     reported adverse events were <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (6.9%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (6.1%), <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>
                     (i.e., <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span>) (6.1%), <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> (4.0%), and
                     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (3.8%). Protocol-defined <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (i.e., 3 or more watery stools in
                     one day or 2 watery stools per day for 2 consecutive days as recorded on diary
                     cards) occurred in 12.9% of patients. </p>
<p>A double-blind, randomized, clinical study compared Amoxicillin and
                     Clavulanate Potassium 600 mg/42.9 mg per 5 mL (90/6.4 mg/kg/day, divided every
                     12 hours) to AMOXICILLIN AND CLAVULANATE POTASSIUM (45/6.4 mg/kg/day, divided
                     every 12 hours) for 10 days in 450 pediatric patients (3 months to 12 years)
                     with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. The primary objective of the study was to compare the
                     safety of Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL to
                     AMOXICILLIN AND CLAVULANATE POTASSIUM. There was no statistically significant
                     difference between treatments in the proportion of patients with 1 or more
                     adverse events. The most frequently reported adverse events for Amoxicillin
                     and Clavulanate Potassium 600 mg/42.9 mg per 5 mL and the comparator of
                     AMOXICILLIN AND CLAVULANATE POTASSIUM were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> (11.9% versus 6.8%),
                     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (6.5% versus 7.7%), <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> (i.e., <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span>, 6.0% versus
                     4.8%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (5.5% versus 3.9%), and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span> (3.0% versus
                     9.2%), respectively. The frequencies of protocol-defined <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> with
                     Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5 mL(11.1%) and
                     AMOXICILLIN AND CLAVULANATE POTASSIUM (9.4%) were similar (95% confidence
                     interval on difference: â€“4.2% to 7.7%). Only 2 patients in the group treated
                     with Amoxicillin and Clavulanate Potassium 600 mg/42.9 mg per 5mL and 1 patient
                     in the group treated with AMOXICILLIN AND CLAVULANATE POTASSIUM were withdrawn
                     due to <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. </p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_ff1d8c9c-0259-4b5b-a0ce-98f38165e7f5"></a><a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<ul class="Disk">
<li>Clinical and Laboratory Standards Institute (CLSI). Performance Standards
                        for Antimicrobial Susceptibility Testing â€“ 21st Informational Supplement.
                        CSLI Document M100-S21. CLSI, 940 West Valley Rd., Suite 1400, Wayne, PA
                        19087, 2011.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). Methods for
                        Antimicrobial Susceptibility Testing of Anaerobic Bacteria â€“ Approved
                        Standard 7th ed. CSLI Document M11-A7. CLSI, 940 West Valley Rd., Suite
                        1400, Wayne, PA 19087, 2007.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). Methods for
                        Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow
                        Aerobically; Approved Standard â€“ 8th ed. CLSI Document M07-A8. CLSI, 940
                        West Valley Rd., Suite 1400, Wayne, PA 19087, 2009.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). Performance
                        Standards for Antimicrobial Disk Susceptibility Test; Approved Standard â€“
                        10th ed. CLSI Document M02-A10. CLSI, 940 West Valley Rd., Suite 1400,
                        Wayne, PA 19087, 2009.</li>
<li>Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of
                        penicillin and cephalosporin ingestions in children less than six years of
                        age. <span class="Italics">Vet Hum Toxicol</span>
                     1988;30:66-67.</li>
</ul>
<br><br><p class="First">CLINITEST is a registered trademark of Miles, Inc.</p>
<p>CLINISTIX is a registered trademark of Bayer Corporation.</p>
<p>FLAVORx is a trademark of FLAVORx. Inc.<br><br></p>
<p>Mfd. by:</p>
<p>Dr. Reddy's Laboratories Inc.,</p>
<p>Bridgewater, NJ 08807</p>
<p>Repackaged By:<br> Aidarex Pharmaceuticals, LLC.<br> Corona, CA 92880</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_dff81a5f-9911-4548-806c-b258e741511d"></a><a name="section-15"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First"><span class="Bold">NDC 33261-0970-01</span></p>
<p><span class="Bold">600 mg/42.9 mg per 5 mL</span></p>
<p><span class="Bold">AMOXICILLIN/CLAVULANATE POTASSIUM </span></p>
<p><span class="Bold"><span class="Italics">powder for oral suspension</span></span></p>
<p>When reconstituted, each 5 mL contains:</p>
<p><span class="Bold"><span class="Italics">AMOXICILLIN,</span> 600 MG,</span></p>
<p>as the trihydrate</p>
<p><span class="Bold"><span class="Italics">CLAVULANIC ACID,</span> 42.9 MG, </span></p>
<p>as clavulanate potassium</p>
<p>200Â mL (when reconstituted)</p>
<p>R<span class="Sub">x</span> only</p>
<p><span class="Bold">Directions for mixing:</span></p>
<p>1. Tap bottle until all powder flows freely. ADD 70 mL OF WATER IN TWO
                     PARTS. <br>2. Add approximately 2/3 of the water for reconstitution. Shake vigorously.<br>
                     3. Add remaining water; shake vigorously. </p>
<p><span class="Bold">Dosage</span>: Administer every 12 hours. See accompanying prescribing
                     information.</p>
<p><span class="Bold">Phenylketonurics</span>: Contains phenylalanine 7 mg per 5 mL.</p>
<p><span class="Bold">Keep tightly closed. </span></p>
<p><span class="Bold">Shake well before using. </span></p>
<p><span class="Bold">Must be refrigerated. </span></p>
<p><span class="Bold">Discard after 10 days.</span></p>
<p>Use only if inner seal is intact.</p>
<p><span class="Bold">Net contents</span>: Equivalent to 9 g
                     amoxicillin and 0.643 g clavulanic acid.</p>
<p>Store dry powder at room temperature.</p>
<p>Mfd. By: Dr. Reddy's Laboratories Inc.,</p>
<p>Bridgewater, NJ 08807</p>
<p>Repackaged By:<br> Aidarex Pharmaceuticals, LLC.<br> Corona, CA 92880</p>
<p>I1111</p>
<p>150035376</p>
<div class="Figure"><img alt="IMAGE LABEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d13d3912-49e2-4a08-a62e-239730b15cd9&amp;name=amox-clav-pot-600-42-9-mg--5ml-sus-200ml-for-dr-re-3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMOXICILLIN AND CLAVULANATE POTASSIUMÂ 		
					</strong><br><span class="contentTableReg">amoxicillin and clavulanate potassium powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:33261-970(NDC:43598-203)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMOXICILLIN</strong> (AMOXICILLIN ANHYDROUS) </td>
<td class="formItem">AMOXICILLIN ANHYDROUS</td>
<td class="formItem">600Â mg Â inÂ 5Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CLAVULANATE POTASSIUM</strong> (CLAVULANIC ACID) </td>
<td class="formItem">CLAVULANIC ACID</td>
<td class="formItem">42.9Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">Â Â Â Â </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">STRAWBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:33261-970-01</td>
<td class="formItem">200 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050755</td>
<td class="formItem">06/22/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Aidarex Pharmaceuticals LLC
							(801503249)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2fce4fed-89a2-4fa9-a1b0-a8dc087ae983</div>
<div>Set id: d13d3912-49e2-4a08-a62e-239730b15cd9</div>
<div>Version: 1</div>
<div>Effective Time: 20140325</div>
</div>
</div>Â <div class="DistributorName">Aidarex Pharmaceuticals LLC</div></p>
</body></html>
